MBX Secures $63.5M in Funding Ahead of Clinical Readouts

Funding Amount:
MBX has raised $63.5 million in funding.

Clinical Readouts:
The company is anticipating clinical readouts for its lead candidate, MBX 2109, a parathyroid hormone peptide prodrug.

Phase II Trial:
MBX 2109 is currently in a Phase II trial for the treatment of hypoparathyroidism.

Pipeline Progression:
The funding will support the progression of MBX's pipeline of engineered peptide therapeutics.

Topline Data:
Topline data for the Phase II trial is expected in the third quarter of 2024.